Perceptions, Expectations, Preferences, and Attitudes Toward Premature Ejaculation, Its Diagnosis and Topical Treatment with Fortacin™ Spray: Results from an Expert Panel Discussion

References

• Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation; 2016 Available from: http://uroweb.org/guideline/male-sexualdysfunction/. Accessed 413, 2017.
   Google Scholar
• McMahon CG, Althof SE, Waldinger MD, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the definition of premature ejaculation. J Sex Med. 2008;5:1590–1606. doi:10.1111/j.1743-6109.2008.00901.x18466262
   PubMed Web of Science ®Google Scholar
• Porst H, Burri A. Fortacin™ Spray for the treatment of premature ejaculation. Urologia J. 2017;84(2_suppl):1–10. doi:10.5301/uj.5000275
   PubMedGoogle Scholar
• Shindel A, Nelson C, Brandes S. Urologist practice patterns in the management of premature ejaculation: a nationwide survey. J Sex Med. 2008;5:199–205. doi:10.1111/j.1743-6109.2007.00638.x17971107
   PubMed Web of Science ®Google Scholar
• Porst H, Burri A. Novel treatment for premature ejaculation in the light of currently used therapies: a review. Sex Med Rev. 2019;7(1):129–140. doi:10.1016/j.sxmr.2018.05.00130057136
   PubMed Web of Science ®Google Scholar
• Puppo V, Puppo G. Comprehensive review of the anatomy and physiology of male ejaculation: premature ejaculation is not a disease. Clin Anat. 2016;29(1):111–119. doi:10.1002/ca.2265526457680
   PubMedGoogle Scholar
• Palmieri A, Imbimbo C, Longo N, et al. Ejaculatory abstinence influences intravaginal ejaculatory latency time: results from a prospective randomized trial. Urol Int. 2012;88(4):459–462. doi:10.1159/00033705722456105
   PubMed Web of Science ®Google Scholar
• Seo DH, Jeh SU, Choi SM, et al. Diagnosis and treatment of premature ejaculation by urologists in South Korea. World J Men's Health. 2016;34(3):217–223. doi:10.5534/wjmh.2016.34.3.21728053952
   PubMedGoogle Scholar
• Revicki D, Howard K, Hanlon J, Mannix S, Greene A, Rothman M. Characterizing the burden of premature ejaculation from a patient and partner perspective: a multi-country qualitative analysis. Health Qual Life Outcomes. 2008;6:33. doi:10.1186/1477-7525-6-3318474090
   PubMed Web of Science ®Google Scholar
• Broderick GA. Premature ejaculation: on defining and quantifying a common male sexual dysfunction. J Sex Med. 2006;3 Suppl 4:295–302. doi:10.1111/j.1743-6109.2006.00304.x16939473
   PubMed Web of Science ®Google Scholar
• Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med. 2005;2:492–497. doi:10.1111/j.1743-6109.2005.00070.x16422843
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Patrick DL, Rowland DL, Bull SA, Tesfaye F, Rothman M. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from Phase III trials with dapoxetine. BJU Int. 2008;102(7):824–828. doi:10.1111/j.1464-410X.2008.07845.x18647300
   PubMed Web of Science ®Google Scholar
• Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: the central role of perceived control. J Sex Med. 2007;4(3):780–788. doi:10.1111/j.1743-6109.2007.00464.x17419817
   PubMed Web of Science ®Google Scholar
• Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med. 2007;4(4 Pt 1):1028–1037. doi:10.1111/j.1743-6109.2007.00528.x17627747
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ. Current and future pharmacotherapies of premature ejaculation. J Sex Med. 2006;3(suppl 4):332–341. doi:10.1111/j.1743-6109.2006.00309.x16939478
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Heintz JW. Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006;7:473–478. doi:10.1007/s11934-006-0057-217052444
   PubMedGoogle Scholar
• Sharlip I. Diagnosis and treatment of premature ejaculation: the physician’s perspective. J Sex Med. 2005;2(suppl 2):103–109. doi:10.1111/j.1743-6109.2005.20370.x16422796
   PubMed Web of Science ®Google Scholar
• Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int. 2007;100(3):493–501. doi:10.1111/j.1464-410X.2007.07051.x17608824
   PubMed Web of Science ®Google Scholar
• Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002;34(6):356–359. doi:10.1046/j.1439-0272.2002.00511.x12472618
   PubMed Web of Science ®Google Scholar
• Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004;93(7):1018–1021. doi:10.1111/j.1464-410X.2003.04773.x15142155
   PubMed Web of Science ®Google Scholar
• McMahon CG. Emerging and investigational drugs for premature ejaculation. Transl Androl Urol. 2016;5(4):487–501. doi:10.21037/tau.2016.04.0227652222
   PubMed Web of Science ®Google Scholar
• Porst H, McMahon CG, Althof SE, et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two Phase 3 dapoxetine trials. J Sex Med. 2010;7(6):2231–2242. doi:10.1111/j.1743-6109.2010.01820.x20412423
   PubMed Web of Science ®Google Scholar
• McMahon CG, Jannini EA, Serefoglu EC, Hellstrom WJ. The pathophysiology of acquired premature ejaculation. Transl Androl Urol. 2016;5(4):434–449. doi:10.21037/tau.2016.07.0627652216
   PubMed Web of Science ®Google Scholar
• Butcher MJ, Zubert T, Christiansen K, Carranza A, Pawlicki P, Seibel S. Topical agents for premature ejaculation: a review. Sex Med Rev. 2020;8(1):92–99. doi:10.1016/j.sxmr.2019.03.00330987933
   PubMed Web of Science ®Google Scholar
• Mondaini N, Fusco F, Cai T, et al. Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Urology. 2013;82:620–624. doi:10.1016/j.urology.2013.05.01823987156
   PubMed Web of Science ®Google Scholar
• McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524–539. doi:10.1111/j.1743-6109.2010.02097.x21059176
   PubMed Web of Science ®Google Scholar
• Park HJ, Park NC, Kim TN, et al. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study. J Sex Med. 2017;5(2):e99- e105. doi:10.1016/j.esxm.2017.02.003
   PubMed Web of Science ®Google Scholar
• Jern P, Johansson A, Piha J, et al. Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting. Int J Impot Res. 2015;27(2):75–80. doi:10.1038/ijir.2014.3725410962
   PubMed Web of Science ®Google Scholar